Bill
Bill > S2875
NJ S2875
NJ S2875Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices.
summary
Introduced
01/13/2026
01/13/2026
In Committee
01/13/2026
01/13/2026
Crossed Over
Passed
Dead
Introduced Session
2026-2027 Regular Session
Bill Summary
This bill exempts drug manufacturers and wholesale drug distributors from the requirement of being a licensed pharmacist when they are engaged in the distribution of dialysate drugs or devices to patients with end-stage renal disease under certain circumstances. Under the bill, drug manufacturers and wholesale drug distributors would not be subject to pharmacist licensing requirements to the extent that they are engaged in the distribution of dialysate drugs or devices necessary to perform home dialysis on patients with end-stage renal disease. For the purposes of the bill, the following would be required of the drugs and devices: (1) approval by the United States Food and Drug Administration; (2) be held by an entity that is properly registered; (3) be held and delivered in original, sealed labeled packaging; (4) delivery only by the manufacturer or the manufacturer's agent and only upon receipt of a physician's order; (5) delivery is made to a patient, the patient's designee, a health care provider, or an institution for administration or delivery of the dialysis therapy to the patient; and (6) periodic oversight of manufacturers and distributors by a licensed pharmacist.
AI Summary
This bill exempts drug manufacturers and wholesale drug distributors from needing a pharmacist license when distributing specific dialysis-related drugs and devices to patients with end-stage renal disease (ESRD) who are undergoing home dialysis. This exemption applies only if the drugs and devices are approved by the U.S. Food and Drug Administration (FDA), are properly registered and held by the manufacturer or their agent in original, sealed packaging, and are delivered by the manufacturer or their agent directly to the patient, their designee, or a healthcare provider upon a physician's order. Additionally, the manufacturer must contract with a consultant pharmacist to conduct weekly quality assurance assessments of home dialysis drug storage and distribution. This change aims to streamline the distribution process for essential home dialysis supplies for ESRD patients.
Committee Categories
Business and Industry
Sponsors (3)
Last Action
Introduced in the Senate, Referred to Senate Commerce Committee (on 01/13/2026)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.njleg.state.nj.us/bill-search/2026/S2875 |
| BillText | https://pub.njleg.gov/Bills/2026/S3000/2875_I1.HTM |
Loading...